Analysis of current pipeline drugs with the potential to become blockbusters by 2008, and segmentation by company and therapy area
Introduction
This analysis identifies the 18 drugs currently in the pipeline that Datamonitor forecasts have the potential to become blockbusters by 2008. By segmenting the pipeline blockbusters by company and by therapy area, the brief identifies the winners and losers in the battle for the next generation of best sellers
Key Reasons To Purchase This Profile
- Understand why AstraZeneca and Eli Lilly are forecast to be the major winners in the race for new blockbusters
- Evaluate the therapeutic breakdown of the next generation of blockbusters and understand why cardiovascular disease will continue to dominate the market
